Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early immune events during SARS-CoV-2 infection impact memory T and B cell responses.

Communications biology·2026
Same author

HIV virion capturing liposomes for therapeutic vaccination.

Biomaterials·2026
Same author

HIV Virion Capturing Liposomes for Therapeutic Vaccination.

bioRxiv : the preprint server for biology·2025
Same author

Monovalent Lectin Microvirin Utilizes Hydropathic Recognition of HIV-1 Env for Inhibition of Virus Cell Infection.

Viruses·2025
Same author

The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine.

Research square·2024
Same author

Injectable Granular Hydrogels Enable Avidity-Controlled Biotherapeutic Delivery.

ACS biomaterials science & engineering·2024

Related Experiment Video

Updated: Jul 5, 2026

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

Structure-based rationale for interleukin 5 receptor antagonism.

Tetsuya Ishino1, Adrian E Harrington, Hosahudya Gopi

  • 1Drexel University College of Medicine, Department of Biochemistry and Molecular Biology, Philadelphia, PA 19102-1192, USA.

Current Pharmaceutical Design
|May 14, 2008
PubMed
Summary

Human interleukin 5 (IL5) drives eosinophil activation, contributing to inflammatory diseases. Researchers identified a peptide inhibitor (AF17121) that blocks IL5Ralpha, offering potential treatments for hyper-eosinophilic conditions.

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Related Experiment Videos

Last Updated: Jul 5, 2026

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Human interleukin 5 (IL5) is a key cytokine regulating eosinophil function.
  • IL5 signaling involves IL5 receptor alpha (IL5Ralpha) and beta c subunits.
  • IL5 and eosinophilia are implicated in inflammatory and myeloproliferative diseases.

Purpose of the Study:

  • To elucidate molecular mechanisms of IL5-IL5Ralpha interaction.
  • To identify and characterize peptide inhibitors of IL5Ralpha.
  • To provide a basis for developing novel therapeutics for hyper-eosinophilic diseases.

Main Methods:

  • Mutational analysis of IL5Ralpha and IL5 interactions.
  • Peptide inhibitor screening and characterization (AF17121).
  • Homology modeling of IL5Ralpha structure.

Main Results:

  • Charge-complementary regions are critical for IL5-IL5Ralpha binding.
  • Cyclic peptide AF17121 specifically binds IL5Ralpha, mimicking IL5.
  • A key pharmacophore in AF17121 and its binding sites in IL5Ralpha were identified.

Conclusions:

  • Peptide AF17121 serves as a model for developing potent peptidomimetic inhibitors.
  • These inhibitors can be used as research tools to study eosinophilia.
  • Potential therapeutic leads for treating hyper-eosinophilic diseases like asthma and eosinophilic esophagitis.